The tenth World Federation of Hemophilia (WFH) Global Forum on Research and Treatment Products for Bleeding Disorders will take place in Montreal, Canada, on November 8 to 10, 2017. The event will feature a unique program focused on the latest research in hemophilia, and current issues in safety, supply, and access to treatment products.
Forum participants will include a broad range of stakeholders from the global bleeding disorders community, including people with hemophilia and other inherited bleeding disorders, hematologists and other clinicians, allied health professionals, academic and clinical researchers, blood services officials, regulators, not-for-profit community members, and industry experts.
The program will cover the topics that are changing the world of bleeding disorders today. For example, experts from around the world will hold talks on the challenges of inhibitor development, the roll-out of extended half-life products, affording new treatments, epidemiology, gene therapy, new and novel hemophilia therapies, and an update on plasma-derived product risks.
There will also be presentations on the WFH Humanitarian Aid Program and the impact it has had around the world over the last year. Participants will also be able to take part in important discussions, and the talk “How will we afford new biological medicines?” and a discussion of clinical trial risks will be covered. Data collection efforts at the WFH will also be explored, including updates on the recently-approved WFH World Bleeding Disorders Registry (WBDR), which will roll out gradually in countries around the world this fall.
“The program for this year’s Global Forum really is very rich,” explains Donna Coffin, WFH Research and Public Policy Director. “There are some very encouraging developments happening in hemophilia today, and the sheer range of topics being covered in the program is a testament to that.”
To find out more about the tenth WFH Global Forum, and to register, click here.